CN113164599A - 抗pd-l1单克隆抗体治疗癌症的用途 - Google Patents
抗pd-l1单克隆抗体治疗癌症的用途 Download PDFInfo
- Publication number
- CN113164599A CN113164599A CN201980081462.1A CN201980081462A CN113164599A CN 113164599 A CN113164599 A CN 113164599A CN 201980081462 A CN201980081462 A CN 201980081462A CN 113164599 A CN113164599 A CN 113164599A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (36)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018115813243 | 2018-12-24 | ||
CN201811581324 | 2018-12-24 | ||
PCT/CN2019/127891 WO2020135415A1 (zh) | 2018-12-24 | 2019-12-24 | 抗pd-l1单克隆抗体治疗癌症的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113164599A true CN113164599A (zh) | 2021-07-23 |
CN113164599B CN113164599B (zh) | 2023-08-01 |
Family
ID=71127637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980081462.1A Active CN113164599B (zh) | 2018-12-24 | 2019-12-24 | 抗pd-l1单克隆抗体治疗癌症的用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113164599B (zh) |
WO (1) | WO2020135415A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107001463A (zh) * | 2014-08-05 | 2017-08-01 | 中美冠科生物技术(太仓)有限公司 | 抗pd‑l1抗体 |
CN107207593A (zh) * | 2014-12-09 | 2017-09-26 | 雷纳神经科学公司 | 抗pd‑1抗体及其使用方法 |
WO2017210453A1 (en) * | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
CN107667119A (zh) * | 2015-05-12 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
CN108026173A (zh) * | 2015-06-12 | 2018-05-11 | 百时美施贵宝公司 | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 |
CN109195989A (zh) * | 2016-05-26 | 2019-01-11 | 默克专利股份有限公司 | 用于癌症治疗的pd-1/pd-l1抑制剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY193229A (en) * | 2015-06-16 | 2022-09-26 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
-
2019
- 2019-12-24 WO PCT/CN2019/127891 patent/WO2020135415A1/zh active Application Filing
- 2019-12-24 CN CN201980081462.1A patent/CN113164599B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107001463A (zh) * | 2014-08-05 | 2017-08-01 | 中美冠科生物技术(太仓)有限公司 | 抗pd‑l1抗体 |
CN107207593A (zh) * | 2014-12-09 | 2017-09-26 | 雷纳神经科学公司 | 抗pd‑1抗体及其使用方法 |
CN107667119A (zh) * | 2015-05-12 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
CN108026173A (zh) * | 2015-06-12 | 2018-05-11 | 百时美施贵宝公司 | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 |
CN109195989A (zh) * | 2016-05-26 | 2019-01-11 | 默克专利股份有限公司 | 用于癌症治疗的pd-1/pd-l1抑制剂 |
WO2017210453A1 (en) * | 2016-06-02 | 2017-12-07 | Bristol-Myers Squibb Company | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
Non-Patent Citations (1)
Title |
---|
杨明子;宋玉琴;朱军;: "PD-1/PD-L1在复发/难治经典霍奇金淋巴瘤中的应用进展", 中国医学前沿杂志(电子版), no. 12, pages 6 - 11 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020135415A1 (zh) | 2020-07-02 |
CN113164599B (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12083112B2 (en) | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer | |
US11866509B2 (en) | Humanized antibodies against CEACAM1 | |
JP6783312B2 (ja) | がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ | |
JP6586087B2 (ja) | Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療 | |
US20160031990A1 (en) | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers | |
TW202233239A (zh) | 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體 | |
WO2021228178A1 (en) | Compositions and methods for treating cancer | |
WO2020211804A1 (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
CN113318226A (zh) | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 | |
CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
WO2021155840A1 (zh) | 抗pd-1抗体在治疗恶性肿瘤中的用途 | |
CN113365659B (zh) | 抗pd-l1抗体治疗头颈癌的用途 | |
US11427647B2 (en) | Polynucleotides encoding humanized antibodies against CEACAM1 | |
CN113164599B (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
CN113117072A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
US20240092934A1 (en) | Assessment of ceacam1 expression on tumor infiltrating lymphocytes | |
WO2024208253A1 (en) | Compositions and methods for treating solid tumors with anti-btla as combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Xiquan Inventor after: Wang Xunqiang Inventor after: Zhao Wei Inventor after: Xiong Zhengjiang Inventor after: Su Nan Inventor after: Wu Ruonan Inventor after: Shao Xiaowen Inventor after: Zhang Chi Inventor after: Yan Yunxia Inventor before: Zhang Xiquan Inventor before: Wang Xunqiang Inventor before: Zhao Wei Inventor before: Xiong Zhengjiang Inventor before: Su Nan Inventor before: Wu Ruonan Inventor before: Shao Xiaowen Inventor before: Zhang Chi Inventor before: Yan Yunxia |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |